Preparation and application of human serum albumin-ruthenium inorganic medicine compound

A technology of human serum albumin and inorganic drugs, applied in the field of anti-tumor drugs, can solve problems such as toxic and side effects, achieve the effects of reducing toxicity, high vascular permeability and retention rate, and improving targeting

Inactive Publication Date: 2013-12-25
GUANGXI NORMAL UNIV
View PDF0 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, we have to face a reality: anti-tumor inorganic drugs are still a double-edged sword. While treating diseases, they will inevitably produce many side effects. Although KP1019 has completed the first phase of clinical trials, it still has very toxic side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation and application of human serum albumin-ruthenium inorganic medicine compound
  • Preparation and application of human serum albumin-ruthenium inorganic medicine compound
  • Preparation and application of human serum albumin-ruthenium inorganic medicine compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Embodiment 1: Preparation of human serum albumin-KP1019 ruthenium inorganic drug complex

[0024] KP1019 was prepared according to the literature: indazole (0.6g; 5.1mmol) was dissolved in 8ml of 12N HCl at 70°C, 2ml of Ru(Ⅲ) solution was added to the hot solution, stirred at 80-90°C for 15 minutes, and immediately appeared An ocher-colored substance appeared, continued stirring to remove HCl residues, filtered, washed with ethanol and ether, and dried in vacuo to obtain 0.296 g of the product, with a yield of 87%. The prepared KP1019 drug was weighed and prepared into a 100mM solution with DMSO, and human serum albumin (HSA) was prepared into a 1.5mM solution with secondary deionized water. The DMSO solution of KP1019 and the HSA aqueous solution were mixed at a ratio of 1:1, the content of DMSO was not more than 5%, and incubated at 4°C for 24 hours. Concentrate the mixture of HSA and ruthenium inorganic anti-cancer drugs, wash it repeatedly with deionized water twic...

Embodiment 2

[0025] Embodiment 2: Structure determination of human serum albumin-KP1019 ruthenium inorganic drug complex

[0026] Mix HSA (1.5mM, 100μL), saturated hexadecanoic acid (2.5mM, 960μL), and drug (100mM, 1.5μL), incubate for 24 hours, centrifuge to remove the precipitate, then concentrate, wash repeatedly with deionized water twice, and finally Concentrate to 100 μL and incubate albumin suitable for X-ray diffraction by gas phase diffusion method (26-30% PEG3350, 5% glycerol, 5% 2-methyl-1,3-propanediol) in a sitting drop plate - Fatty acid-metal drug complex crystals. Crystal data were collected using the Shanghai Synchrotron Radiation Facility. After processing the data with HKL2000, use the molrep program of ccp4 to use the protein with strong homology with the amino acid sequence of the protein in the protein database as a template, quickly rotate and translate the function to find a suitable template, and integrate it. If there is no protein with strong homology in the ex...

Embodiment 3

[0028] Example 3: Effect of ruthenium inorganic drug / human serum albumin-KP1019 ruthenium inorganic drug complex on tumor cell proliferation in vitro

[0029] Digest the confluent monolayer cells with trypsin, collect the cells into the serum-containing medium, add 200 μl of cell suspension to each well of the tenth row in the middle of a flat-bottomed 96-well plate, and add 0.5×10 3 -10×10 3 cells, place the culture plate in CO 2 In the incubator, incubate in a humid environment at 37°C. After the cells adhere to the wall, add the above-mentioned different concentrations of ruthenium inorganic drugs prepared above and albumin carrier ruthenium inorganic drugs for 48 hours, and then add MTT (3-(4, 5-dimethylthiazole-2)-2,5-diphenyltetrazolium bromide), after continuing to cultivate for 4 hours, discard the supernatant, add 100ml of DMSO, and measure the optical density at 570nm on a microplate reader. Repeat 3 times in a row. The half inhibitory rate value of the ruthenium ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses preparation and application of a human serum albumin-KP1019 ruthenium inorganic medicine compound. KP1019 and the human serum albumin are incubated, the mixture is concentrated, the concentrated mixture is repeatedly washed by secondary deionized water till the DMSO content is smaller than 0.01 percent, then concentration is performed to obtain the human serum albumin-KP1019 ruthenium inorganic medicine compound, and the compound is prepared into an injection, tablets, pills, capsules, a suspending agent or an emulsion to treat breast cancer, stomach cancer, lung cancer, colon cancer or liver cancer. The compound has high vascular permeability and retention rate, the medicine selectivity gathers in tumor cells while not influencing normal cells, the targeting of the ruthenium inorganic medicine is remarkably improved and the toxicity is greatly lowered.

Description

technical field [0001] The invention relates to antitumor drugs, in particular to the preparation and application of human serum albumin-KP1019 ruthenium inorganic drug complexes. Background technique [0002] In recent years, ruthenium complexes have been extensively studied as new anticancer drugs. Due to the unique physical and chemical properties of ruthenium complexes, it is generally believed internationally that ruthenium complexes are low-toxic, easy to absorb and excreted quickly in the body. At present, hundreds of ruthenium complexes have been synthesized, and KP1019 has completed Phase I clinical trials and is entering Phase II clinical trials. However, we have to face a reality: anti-tumor inorganic drugs are still a double-edged sword. While treating diseases, they inevitably produce many side effects. Although KP1019 has completed the first phase of clinical trials, it still has very toxic side effects. Obviously, how to improve the intelligence of anti-tumo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/555A61K47/42A61P35/00
Inventor 杨峰梁宏李梅张耀
Owner GUANGXI NORMAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap